Form 8-K Compass Therapeutics, For: May 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Compass Therapeutics (CMPX) PT Lowered to $7 at Jefferies
May 13, 2024 1:21 PM EDTJefferies analyst Maury Raycroft lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $7.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "CMPX updated pivotal BTC ph.II/III data guidance to 1Q25 (vs YE24), which we think is incremental given that enrollment... More



